ProjectKAKS – Präklinische Testung CD171- undGD2-spezifischer CAR-TZelltherapie zur Behandlung des Retinoblastoms in vivo
Basic data
Acronym:
KAKS
Title:
Präklinische Testung CD171- undGD2-spezifischer CAR-TZelltherapie zur Behandlung des Retinoblastoms in vivo
Duration:
01/01/2019 to 31/12/2019
Abstract / short description:
In this project, we want to validate date, which were generated by the work group of Dr. med. Kunkele i.R. in a preliminary project (KAKS 2017 / C05f) in vivo. In this preliminary project, a specific form of adoptive T-cell therapy was evaluated as a treatment approach for retinoblastoma. Adoptive T-cell therapy means that the patient's immune system is artificially enhanced to destroy cancer cells better and more effectively.
As a next important step in the preclinical evaluation of CAR-T cell therapy, we are now planning to validate the findings obtained in vitro on the mouse model in vivo.
As a next important step in the preclinical evaluation of CAR-T cell therapy, we are now planning to validate the findings obtained in vitro on the mouse model in vivo.
Keywords:
Adoptive T-Zelltherapie
Retinoblastom
CAR-T-Zelltherapie
mouse model
Mausmodell
Krebs
Involved staff
Managers
Schraermeyer, Ulrich
Center for Ophthalmology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Local organizational units
Center for Ophthalmology
Hospitals and clinical institutes
Faculty of Medicine
Faculty of Medicine
Funders
Deutschland, Nordrhein-Westfalen, Germany